SCHEDULE: Jorey Chernett Increases Stake in Neuronetics

Jorey Chernett has filed an amendment to Schedule 13D, reporting increased beneficial ownership of Neuronetics, Inc. common stock to 15.17%.

Summary

• Jorey Chernett has filed Amendment No. 2 to Schedule 13D, updating their beneficial ownership of Neuronetics, Inc. common stock.
• As of May 26, 2026, Chernett beneficially owns 10,553,988 shares, representing approximately 15.17% of the outstanding shares.
• These shares were acquired using personal funds for an aggregate purchase price of approximately $20,619,936.
• The filing details transactions in Neuronetics, Inc. securities made since the previous amendment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily a disclosure of increased ownership rather than a performance update. The sentiment is driven by the factual reporting of transactions and ownership percentages.

Positives

• Increased beneficial ownership by a significant stakeholder, Jorey Chernett, to 15.17%.
• Acquisition of shares was funded by personal funds, indicating personal conviction in the investment.

Risks

• The filing does not explicitly mention any risks. However, any investment in a publicly traded company carries inherent market risks.
• Concentration of ownership by a single individual could potentially lead to influence over corporate decisions, which may or may not align with other shareholders' interests.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company. It solely reports on past transactions and current beneficial ownership.

Industry Context

StockSavvy.ai notes that significant increases in beneficial ownership, as reported in Schedule 13D filings, often signal a substantial investor's conviction or potential for activist involvement. This filing indicates Jorey Chernett's growing stake in Neuronetics, Inc., a company operating in the medical technology sector, which is subject to innovation cycles and regulatory scrutiny.

Stakeholder Impact

• Shareholders: May view the increased stake as a sign of confidence from a significant investor, potentially influencing market perception. However, it also concentrates voting power.
• Management: May need to consider the perspective and potential influence of a 15.17% shareholder in strategic decision-making.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Continued monitoring of Jorey Chernett's beneficial ownership and any further filings.
• Observation of Neuronetics, Inc.'s strategic decisions and performance, which may be influenced by significant stakeholders.

Key Dates

Recommendation

The filing reports an increase in beneficial ownership by Jorey Chernett, indicating a significant investor's continued or increased interest in Neuronetics, Inc. However, without accompanying company performance data or strategic announcements, it is prudent to hold and await further developments or company disclosures before making a stronger recommendation.

Keywords

Neuronetics, Inc., Schedule 13D, Beneficial Ownership, Common Stock, Jorey Chernett, SEC Filing, Amendment, Investment